口服酪氨酸酶抑製劑（TKI）療法是腎細胞癌（RCC）治療中的一大進步。目前有多種此類藥物可選，其中使用最多的是舒尼替尼，可將無進展生存期延長至11個月。然而隨著治療時間的延長，藥物副反應也增多，會降低病人的生活質量。因此，臨床醫師與患者都期待能夠製定出一套監測、治療和處理副反應的標準。雖然目前有很多醫師在總結處理這些問題的經驗，並提出了相關的建議，但這些畢竟隻是單中心的經驗總結，且有的醫療中心病例數較少。
參考文獻
1. Motzer RJ, Hutson TE, Tomczak P,et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590.
2. Motzer RJ, Hutson TE, Tomczak P, et al. (2007) Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124.
3. Hudes G, Carducci M, Tomczak P, et al.(2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281.
4. Grunwald V, Heinzer H, Fiedler W (2007) Managing side efects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 30:519–524.
5. Grunwald V, Soltau J, Ivanyi P,et a.(2009) Molecular targeted therapies for solid tumors: management of side efects. Onkologie 32:129–1386.
6. Eskens FA, Verweij J (2006) The clinical toxicity proWle of vascular endothelial growth factor (vegf) and vascular endothelial growth factor receptor (vegfr) targeting angiogenesis inhibitors; a review. Eur J Cancer 42:3127–3139.
7. Schmidinger M, Zielinski CC, Vogl UM, et al.(2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212.
8. Speca J, Yenser S, Creel P, George D (2006) Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer 5(Suppl 1):S24–S30.
9. Azizi M, Chedid A, Oudard S (2008) Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 358:95–97.
10. Porta C, Paglino C, Imarisio I, et al. (2007) Uncovering pandora’svase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7:127–134.
11. Desai JG, Pavlakis H, McAarthur N, et al. (2007) Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management.Asia-Pacific Journal of Clinical Oncology 3:167–176.
12. Bhargava P (2009) Vegf kinase inhibitors: How do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297:R1–R5.
13. Chu TF, Rupnick MA,et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019.
14. Negrier S, Ravaud A (2007) Optimisation of sunitinib therapy in metastatic renal cell carcinoma: Adverse-event management. Eur J Cancer Suppl 5:12–19.
15. Summary of product characteristics; sutent
16. Di Lorenzo G, Autorino R, Bruni G, et al.(2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535–1542.
17. Ivanyi P, Winkler T, Ganser A, Reuter C, Grunwald V (2008) Novel therapies in advanced renal cell carcinoma: Management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 105:232–237.
18. Izzedine H, Ederhy S, Goldwasser F, et al. A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807–815.
19. Bhojani N, Jeldres C, Patard JJ, et al. (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsiroli-mus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930.
20. National comprehensive cancer network21 (nccn). Clinical practice guidelines in oncology . Cancer-related fatigue (v.2.2007).Available at: http://www.Nccn.Org/professionals/physician_gls/pdf/fatigue.Pdf, 2007
21. Wood L (2006) Managing the side eVects of sorafenib and sunitinib. Community Oncol 3:558–562.
22. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R,Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma:Recommendations for management of side eVects. CanUrol Assoc J 1:S41–S54.
23. Staehler M, Haseke N, Schoppler G, et al. (2006) managing the side eVects of angiogenetic inhibitors in metastatic renal cell carcinoma. Urologe A 2006;45:1333–1342; quiz 1343.
24. Houk BE, Bello C, Michaelson MD, et al. (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mrcc): A population pharmacokinetic/pharmacodynamic (pkpd) approach. J clin Oncol ASCO MeetingAbstracts 25 Abstract: 5027.
25. Botchkareva NV, Khlgatian M, Longley BJ, et al. (2001) Scf/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 15:645–658.
26. Rosenbaum SE, Wu S, Newman MA, et a. (2008) Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 16:557–566.
27. Webster-Gandy JD, How C, Harrold K (2007) Palmar-plantar erythrodysesthesia (ppe): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11:238–246.
28. Lacouture ME, Wu S, Robert C, et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001–1011.
29. Esper P, Gale D, Muehlbauer P (2007) What kind of rash is it?: Deciphering the dermatologic toxicities of biologic and targeted therapies. Clin J Oncol Nurs 11:659–666.
30. Pfohler C (2008) US: Cutaneous reactions to molecular targeted therapies. Hautarzt 59:814–820.
我要跟帖
copyright©醫學論壇網 版權所有，未經許可不得複製、轉載或鏡像
京ICP證120392號 京公網安備110105007198 京ICP備10215607號-1 （京）網藥械信息備字（2022）第00160號
